恩替卡韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效研究*

doi:10.3969/j.issn.1672-5069.2023.03.010

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (3): 340-343.doi: 10.3969/j.issn.1672-5069.2023.03.010

恩替卡韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效研究^*

郭晓玲, 张耀武, 李梦桃, 张辉

032200 山西省吕梁市山西医科大学汾阳学院感染病学教研室(郭晓玲,李梦桃,张辉);附属汾阳医院感染性疾病科(张耀武)

收稿日期:2022-11-25 出版日期:2023-05-10 发布日期:2023-05-08
通讯作者: 张耀武,E-mail:zyw5680.@126.com
作者简介:郭晓玲,女,26岁,硕士研究生。研究方向:病毒性肝炎的基础与临床研究。E-mail:gxl961012@126.com
基金资助:
^*山西省应用基础研究项目(编号:201801D221430)

Auxiliary treatment of a herbal compound, Ganshuang granule, with entecavir for patients with chronic hepatitis B

Guo Xiaoling, Zhang Yaowu, Li Mengtao, et al.

Department of Infectious Diseases, Fenyang College, Shanxi Medical University, Lyuliang 032200,Shanxi Province, China

Received:2022-11-25 Online:2023-05-10 Published:2023-05-08

摘要/Abstract

摘要： 目的探讨应用恩替卡韦联合肝爽颗粒治疗慢性乙型肝炎(CHB)患者的近期疗效。方法 2019 年1月～2021年1月我院诊治的CHB患者60例,被随机分为对照组和观察组,每组30例,分别给予恩替卡韦或恩替卡韦联合肝爽颗粒,连续治疗48 w。计算天冬氨酸氨基转移酶/血小板计数比率指数(APRI)、肝纤维化4因子指数(FIB-4),使用FibroTouch行肝硬度检测(LSM),采用放射免疫法检测血清透明质酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PC-Ⅲ)和Ⅳ型胶原(Ⅳ-C),采用ELISA法检测血清白介素-6(IL-6)、转化生长因子-β(TGF-β)、血小板衍生生长因子(PDGF)和C反应蛋白(CRP)。结果治疗后,观察组血清ALT和AST水平显著低于对照组,差异具有统计学意义(P<0.05);两组血清HBV DNA阴转率均为100.0%,而血清HBeAg阴转率均为0.0%,无统计学差异(P>0.05);观察组 APRI、FIB-4和LSM水平分别为(1.02±0.23)、(4.38±0.77)和(7.73±1.53),均显著低于对照组【分别为(1.30±0.33)、(5.26±0.85)和(9.68±2.02),P<0.05】;观察组血清 IL-6、TGF-β、PDGF和CRP水平均显著低于对照组,差异具有统计学意义(P<0.05)。结论应用肝爽颗粒辅助恩替卡韦治疗CHB患者可提高血生化学应答率,可能与其具有一定的抗肝纤维化和抑制炎性反应作用有关,需要进一步观察。

关键词: 慢性乙型肝炎, 恩替卡韦, 肝爽颗粒, 白细胞介素-6, 治疗

Abstract: Objective The purpose of this clinical trial was to investigate the auxiliary treatment of a herbal compound, Ganshuang granule, with entecavir for patients with chronic hepatitis B (CHB). Methods 60 patients with CHB were enrolled in our hospital between January 2019 and January 2021, and were randomly divided into control and observation groups, with 30 cases in each. The patients in the control group received entecavir, and those in the observation were treated with entecavir and a herbal compound, Ganshuang granule, for 48 weeks. The AST to platelet ratio index (APRI), fibrosis 4 score (FIB-4) were obtained, and the liver stiffness measurement (LSM) was determined by FibroTouch scan. Serum interleukin-6(IL-6), transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF) and C-reactive protein (CRP) levels were assayed by ELISA. Results At the end of 48 week treatment, serum ALT and AST levels in the observation group were significantly lower than in the control group (P<0.05); serum HBV DNA loss in the two groups were both 100.0%, and serum HBeAg negative rates were both 0.0% (P>0.05); the APRI, FIB-4 and LSM in the observation group were (1.02±0.23), (4.38±0.77) and (7.73±1.53), all significantly lower than [(1.30±0.33), (5.26±0.85) and (9.68±2.02), respectively, P<0.05] in the control; serum IL-6, TGF-β, PDGF and CRP levels in the observation were much lower than in the control (P<0.05). Conclusion The auxiliary treatment of Ganshuang granule at base of entecavir antiviral therapy could significantly improve biochemical response in patients with CHB, which might be related to the anti-fibrotic effect and inhibition of body inflammatory reaction of the herbal compound.

Key words: Hepatitis B, Entecavir, Herbal medicine, Ganshuang granule, Interleukin-6, Therapy

郭晓玲, 张耀武, 李梦桃, 张辉. 恩替卡韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 340-343.

Guo Xiaoling, Zhang Yaowu, Li Mengtao, et al.. Auxiliary treatment of a herbal compound, Ganshuang granule, with entecavir for patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2023, 26(3): 340-343.

参考文献

[1] Chang M, Yang S. Metabolic signature of hepatic fibrosis:from individual pathways to systems biology.Cells,2019,8(11):1423-1435.
[2] Yu Y,Cui X,Zhao J,et al.Effect of entecavir combined with adefovir dipivoxil on clinical efficacy and TNF-αand IL-6 levels in patients withhepatitisB cirrhosis.J Oncol,2021,2021(1):1-5.
[3] Li H. Advances in anti-hepatic fibrotic therapy with traditional Chinese medicine herbal formula.J Ethnopharmacol,2020,251(1):112-122.
[4] LiWQ,Liu WH,Qian D,et al.Traditional Chinese medicine:an important source for discovering candidate agents against hepatic fibrosis.Front Pharmacol,2022,13(1):1-15.
[5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1)S9-32.
[6] 中国中西医结合学会肝病专业委员会.肝纤维化中西医结合诊疗指南(2019年版).中华肝脏病杂志,2019,27(7):494-504.
[7] Liu J,Liang W,Jing W,et al.Countdown to 2030:eliminating hepatitis B disease,China.Bull World Health Organ,2019,97(3):230-238.
[8] Pietro L,Kosh A,Thomas B,et al.EASL 2017 clinical practice guidelines on the management ofhepatitis B virus infection.J Hepatol,2017,67(2):370-398.
[9] Parola M,Pinzani M.Liver fibrosis:Pathophysiology,pathogenetic targets and clinical issues.Mol Aspects Med,2019,65(1):37-55.
[10] Lok A S.Hepatitis:Long-term therapy of chronic hepatitis B reverses cirrhosis.Nat Rev Gastroenterol Hepatol,2013,10(4):199-200.
[11] Du X,Wang J,Shao L,et al.Histological improvement of long-term antiviral therapy in chronic hepatitis B patients with persistently normal alanine aminotransferase levels.J Viral Hepat,2013,20:328-35.
[12] Lambrecht J,van Grunsven LA,Tacke F.Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis. Expert Opin Pharmacother,2020,21(13):1637-1650.
[13] Wu L,Shen Y,Li F.Non-invasive diagnosis of liver fibrosis:A review of current imaging modalities.Gastroenterol Hepatol,2020,43(4):211-221.
[14] Zhang M,Serna-Salas S,Damba T,et al.Hepatic stellate cell senescence in liver fibrosis:Characteristics,mechanisms and perspectives.Mech Ageing Dev, 2021,199(1): 111572-111583.
[15] An S Y,Petrescu A D,Demorrow S.Targeting certain interleukins as novel treatment options for liver fibrosis.Front Pharmacol,2021,12(1):64-77.
[16] Hou X,Yin S,Ren R,et al.Myeloid-cell-specific IL-6 signaling promotes microrna-223-enriched exosome production to attenuate NAFLD-associated fibrosis.Hepatology,2021,74(1):116-132.
[17] Ngwa D N,Pathak A,Agrawal A.IL-6 regulates induction of C-reactive protein gene expression by activating STAT3 isoforms.Mol Immunol,2022,146(1):50-56.
[18] 刘莉,杨静,李宗云,等.肝爽颗粒对慢性乙型肝炎肝纤维化(S1和S2期)肝郁脾虚兼血瘀证的早期防治疗效.中国实验方剂学杂志,2022,28(11):132-138.

恩替卡韦联合肝爽颗粒治疗慢性乙型肝炎患者疗效研究^*

Auxiliary treatment of a herbal compound, Ganshuang granule, with entecavir for patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张绍全, 林炳亮. 肠道菌群与肝硬化研究进展^*[J]. 实用肝脏病杂志, 2023, 26(3): 313-316.
[2]	陶贞贞, 王永莉, 孙红艳, 王慧芬. 二维剪切波弹性成像诊断慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 328-331.
[3]	赵景, 何秀波, 谌瑾寰. 肝脏剪切波弹性成像联合GGT/PLT比值诊断慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 332-335.
[4]	张丹蕾, 徐静. 艾米替诺福韦治疗慢性乙型肝炎患者早期疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 336-339.
[5]	王云云, 吴万锋, 李黎. 直接抗病毒药物治疗基因1b型慢性丙型肝炎合并2型糖尿病患者疗效及对血糖控制的影响^*[J]. 实用肝脏病杂志, 2023, 26(3): 344-347.
[6]	许海苗, 郑瑞琦, 丁惠国. 匹伐他汀联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 352-355.
[7]	郭银燕, 岳枝, 盖晓冬, 冯艳红, 张杰东. 自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征患者临床和肝组织病理学特征分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 372-375.
[8]	何学元, 马建勋, 杨屹立, 张敏, 潘新民. 布地奈德治疗熊去氧胆酸治疗不应答的原发性胆汁性胆管炎患者疗效及血清氧化应激指标的变化^*[J]. 实用肝脏病杂志, 2023, 26(3): 376-379.
[9]	王俊红, 戴玲, 陈国斌, 杨路平, 周晶. 还原型谷胱甘肽、甘草酸二铵和复方甘草酸苷治疗抗结核药物所致药物性肝损伤患者成本-效益分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 380-383.
[10]	卫栋萍, 韩黎黎, 凌佳慧, 顾晓琴, 曹永峰. 甘草酸二胺与复方甘草酸苷治疗环磷酰胺所致的药物性肝损伤患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 388-391.
[11]	叶丝陶, 黄晓铨, 陈世耀. 血浆纤维蛋白原水平预测乙型肝炎肝硬化患者内镜治疗后食管胃静脉曲张再出血风险效能分析^*[J]. 实用肝脏病杂志, 2023, 26(3): 392-395.
[12]	刘坤, 徐菁, 马竹芳. 托伐普坦联合腹水超滤浓缩回输术治疗肝硬化并发顽固性腹水患者疗效初步研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 396-399.
[13]	唐亮, 陈曦, 王文高, 董超. TACE联合直线加速器三维适形放疗治疗中晚期原发性肝癌患者近期临床疗效研究[J]. 实用肝脏病杂志, 2023, 26(3): 416-419.
[14]	张威, 陈国林, 王航, 余良, 孔祥璐. 合并不同基础疾病的细菌性肝脓肿患者临床特征分析[J]. 实用肝脏病杂志, 2023, 26(3): 424-427.
[15]	张琼, 陈士颖, 夏维. 超声引导下无水乙醇与聚桂醇硬化治疗单纯性肝囊肿患者效果比较研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 428-431.